Delphine Le Louet's questions to Inventiva (IVA) leadership • Q4 2021
Question
Delphine Le Louet of Societe Generale asked for confirmation that the R&D spending levels of 2022 would likely continue into 2023 and 2024. She also questioned the potential risk of delays to the NATIVE trial timeline due to the impact of the situation in Eastern Europe, which affects a significant portion of planned patient recruitment, and how the company would manage the demographic balance of the trial population.
Answer
CFO Jean Volatier confirmed that projected expenses for 2023 are expected to be in the same range as 2022. Executive Frederic Cren addressed the trial recruitment concerns, stating they do not anticipate the situation will jeopardize the overall timeline. He explained that the company is mitigating the loss of 22 sites in Ukraine and Russia by increasing the total number of global sites to 350 and working with CROs to activate new sites in currently open or new countries to maintain recruitment momentum.